A new proposed rule that will allow generic drug makers to update their
own safety warnings on labels has been delayed until the fall of 2015.
The new rule has been labeled as “controversial” because it
would give the makers of generic drugs the ability independently update
safety warnings. This is currently something that only brand-name drug
makers are allowed to do prior to receiving permission from the United
States Food and Drug Administration (FDA).
An article that was recently published on the Wall Street Journal’s
website makes the following comments:
There are concerns that
generic drug labeling might be insufficient to warn patients about the risks associated with
certain generic medications
- Generic drug manufacturers are not required to run tests that prove their
medications are exactly the same as the brand-name variety
When it comes to brand-name and generic drugs, there are many concerns
about warning labels. The complexity and controversy surrounding this
particular issue is the reason for the FDA’s delay in finalizing
the new rule.
At Golomb & Honik, our lawyers are highly experienced in helping
pharmaceutical injury victims. We know the complex laws that govern these cases, and we have
the vast resources necessary to battle large pharmaceutical companies
in court to recover the compensation you deserve.
If you’ve been injured due to the consumption of a generic drug, please
contact Golomb & Honik today to
schedule a free consultation. We serve clients nationwide from our offices in Philadelphia.